Abstract 283P
Background
Worldwide, there are approximately 560 000 new cases diagnosed with head and neck cancer and 300 000 deaths each year. In developing countries including Sub-Saharan Africa, head and neck cancer is rare compared to other cancers. The aims of this study are to estimate the incidence and determine the epidemiological characteristics of head and neck cancer in the population of Niger.
Methods
This is a descriptive retrospective study of head and neck cancer cases, reported to the Niger Cancer Registry in the period 1992-2009. Head and neck cancer includes the following: lip, tongue, mouth (floor, palate and other), salivary glands, tonsils, pharynx (oro-, naso- and hypopharynx), larynx, nose, ear, head and neck not otherwise specified.
Results
In 1992-2009, there were 344 cases diagnosed with head and neck cancer in Niger, which was 4.89% of all cases of cancer reported during this period, with a male-female ratio of 1.49. The incidence rate of head and neck cancer was 2.34 cases per 100 000 persons. Oral cancer was the most common cancer (27.6%), followed by laryngeal and salivary glands cancers (13.1%) and tonsil cancer (10.2%). The mean age at diagnosis of the patients was 42.11±18.24 years. The commonest histological type was squamous cell carcinoma in 27.1% of cases. We registered 11 deaths, with a fatality rate of 3.19%.
Conclusions
Although the incidence rates for head and neck cancers are lower, these cancers include a diverse group of uncommon tumors that frequently are aggressive. Because of the seriousness of cancer in Niger; the health authorities should pay more attention to this pathology through efficient fight strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session